Alnylam Pharmaceuticals, Inc.
- Home
- Companies
- Alnylam Pharmaceuticals, Inc.
- Products
- OXLUMO lumasiran - Prescription ...
OXLUMO lumasiran - Prescription Medication for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
The first and only FDA-approved prescription medication for the treatment of primary hyperoxaluria type 1 (PH1). OXLUMO is a prescription medicine for the treatment of PH1 to lower oxalate in urine in children and adults.
Most popular related searches
Results of the trial:
53% REDUCTION
Patients on OXLUMO had 53% less oxalate in their urine from the start of treatment at month 6 compared to patients treated with placebo
84% OF PATIENTS
84% of patients on OXLUMO had normal (52%) or close-to-normal (32%) oxalate levels* in their urine at month 6 compared with no patients treated with placebo
OXLUMO targets oxalate overproduction at the source.
- In PH1, the liver produces too much oxalate
- OXLUMO works in the liver to reduce the amount of oxalate being made
- By reducing oxalate, OXLUMO targets the cause of PH1 symptoms
OXLUMO works by reducing oxalate production
Introducing the first and only FDA-approved prescription medication for infants, children and adults with primary hyperoxaluria type 1 (PH1).